Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X:

“Myeloma Paper of the Day: Mass spectrometry-based assessment of M-protein in the peripheral blood from patients on phase 3 ATLAS trial during maintenance therapy may have comparable value to BM MRD assessment at the 10(-5) threshold.”

Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma

Authors: Tadeusz Kubicki, Dominik Dytfeld, David Barnidge, Dhananjay Sakrikar, Anna Przybyłowicz-Chalecka, Krzysztof Jamroziak, Pawel Robak, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Tomasz Wróbel, Adam Nowicki, Tomasz Szczepaniak, Anna Łojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Lukasz Szukalski, Agnieszka Końska, Jan  Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Ken Jiang, Jennifer Cooperrider, Andrzej Jakubowiak, and Benjamin Derman.

Source: Robert Orlowski/X

Other insights by Robert Orlowski on OncoDaily.